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ABSTRACT
Aim To report on outcomes of gonioscopy-assisted
transluminal trabeculotomy (GATT) in eyes with
pseudoexfoliative glaucoma (PXG).
Methods Prospective, interventional, non-comparative
case series. A total of 103 eyes from 84 patients with PXG
were enrolled to undergo a 360-degree ab interno
trabeculotomy with gonioscopic assistance using either
a 5.0 polypropylene suture or an illuminated
microcatheter with up to 24 months of follow-up. Main
outcome measures were intraocular pressure (IOP),
number of antiglaucoma medications, success rate (IOP
reduction ≥20% from baseline or IOP between 6 and
21 mm Hg, without further glaucoma surgery) and
complication rate.
Results Mean preoperative IOP was 27.1 mm Hg (95%
CI 25.5 to 28.7) using 2.9 (SD 1.1) glaucoma medications
which decreased postoperatively to 13.0 mm Hg (95% CI
11.5 to 14.4) and 1.0 (SD 1.1) medications at 24 months
(p<0.001). Success rate was 89.2% at 24 months of
follow-up, and complication rate was 2.9%.
Conclusion At 24 months of follow-up, our results for
GATT in PXG demonstrate that this conjunctival sparing
procedure effectively lowers IOP and reduces the
medications with a low complication rate, in this relatively
aggressive glaucoma subtype.
INTRODUCTION
Pseudoexfoliation syndrome (PXS) is an age-related
systemic disease with primarily ocular manifestations
characterised by extracellular deposition of a fibrillar,
whitish-grey proteinaceous substance on the lens,
iris, ciliary epithelium, corneal endothelium, trabecu-
lar meshwork and extraocular tissues.1 PXS is asso-
ciated with numerous extraocular conditions2 and is
also a strong independent risk factor for glaucoma in
patients with ocular hypertension.3
Pseudoexfoliative glaucoma (PXG) is themost com-
mon form of secondary glaucoma worldwide2 with
a worse prognosis than primary open-angle glaucoma
(POAG), as patients may experience larger intraocular
pressure (IOP) fluctuations, greater visual field loss
and optic nerve head damage, reduced response to
medications and faster progression.4 Medical or laser
treatment is recommended as the first-line therapy, but
surgical treatment is often required.5
Minimally invasive glaucoma surgeries (MIGS)
are emerging as an alternative to trabeculectomy,6
which remains the gold standard procedure for
lowering IOP surgically.7 Trabeculotomy reduces
the aqueous outflow resistance through Schlemm’s
canal by making an incision in the trabecular mesh-
work, avoiding bleb formation. The most frequent
approach is ab externo, requiring extensive conjunc-
tival and scleral surgery, similar to standard
trabeculectomy.8 An ab interno approach, via
a clear corneal incision and aided by gonioscopy,
preserves the conjunctiva and sclera and maintains
the option of subsequent filtration surgery.9
With this prospective study, we aim to present the
outcomes of an ab interno approach, the gonioscopy-
assisted transluminal trabeculotomy (GATT), in eyes
with PXG with a follow-up of up to 2 years.
MATERIALS AND METHODS
This was a prospective, interventional, non-
comparative case series of 103 eyes of 84 patients
diagnosed with PXG, who showed glaucoma pro-
gression despite maximal tolerated medical therapy.
All GATT procedures were performed by a single
experienced surgeon (ES) during January 2016 and
May 2018. The study adhered to the tenets of the
Declaration of Helsinki, and Institutional Review
Board/Ethics Committee approval was obtained
from the Commission Cantonale d’Ethique,
Canton of Vaud, Switzerland. All participants pro-
vided written informed consent.
Patient demographic data was documented preo-
peratively as well as medications and best-corrected
visual acuity (BCVA), slit-lamp biomicroscopy,
gonioscopy, funduscopy and IOP measurement by
Goldmann applanation tonometry. Presence of pseu-
doexfoliative material in the angle, lens or at the
pupillary border was confirmed during the preopera-
tive examination. Visual field perimetry and optical
coherence tomography of the optic nerve head were
used to establish the diagnosis of glaucoma.
Surgical procedure
Topical 2% pilocarpine was applied preoperatively.
A standard sterile procedure with application of 5%
iodine drops for 3 min was performed. A paracentesis
was made in the superonasal or inferonasal quadrant
and viscoelastic (HEALON GV, J&J Vision, Florida,
USA) was injected into the anterior chamber, and
a temporal paracentesis was created. The iridocorneal
angle was visualised nasally using a Swan Jacob gonio-
scope. Using a crescent-shaped goniotomy blade,
a horizontal incision of 1–2 mm was made into the
trabecular meshwork. Either an illuminated catheter
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(iTRACK 250A; iScience Interventional, Menlo Park, California,
USA) or a thermally blunted 5.0 polypropylene thread was intro-
duced via a separate paracentesis into this goniotomy incision and
advanced parallel to the iris plane, within Schlemm’s canal, using
microsurgical forceps (diamondised, end-gripping forceps of 25Ga,
FCI Ophtalmics, Paris, France). The catheter or the thread was then
externalised into the anterior chamber, thereby creating a 360° ab
interno trabeculotomy. If a 360° goniotomywas not possible mainly
due to blockage of the microcatheter, the device was inserted in the
opposite direction. The viscoelastic was washed out from the ante-
rior chamber using an irrigation-aspiration system to remove blood,
and then new viscoelastic was again inserted to obtain approxi-
mately a 25% anterior chamber fill. The corneal incisions were
sutured, and subconjunctival steroids were injected at the end of
the procedure. If cataract surgery was needed, the GATT procedure
was performed immediately after standard phacoemulsification and
intraocular lens implantation.
Postoperative protocol
A regimen of topical medications was prescribed as follows.
A combination of topical dexamethasone and chloramphenicol
(Spersadex comp., Théa Pharma, Clermont-Ferrand, France) for
Table 1 Demographic information
n Mean values











BCVA (logMAR) 0.3 (0.3)
MD 11.9 (8.3)





BCVA, best-corrected visual acuity; logMAR, logarithm of the Minimum Angle of Resolution;
MD, mean deviation of 24-2 visual field test.



















1 d 102 27.1 (25.5–28.7) 13.0 (11.6–14.4) 14.1 (12.1–16.0) (52) 2.9 (1.1) 0.2 (0.8) 2.7 (1.4)
1 w 97 27.2 (25.6–28.9) 14.9 (13.4–16.4) 12.3 (10.3–14.4) (45) 2.8 (1.1) 0.3 (0.9) 2.5 (1.5)
3 w 81 27.0 (25.1–28.9) 12.2 (11.2–13.2) 14.8 (12.7–16.9) (55) 2.8 (1.1) 0.5 (0.9) 2.4 (1.5)
6 w 60 27.2 (25.2–29.2) 12.8 (11.9–13.7) 14.4 (12.4–16.4) (53) 2.9 (1.1) 0.4 (1.0) 2.5 (1.6)
3 m 68 27.7 (25.7–29.8) 12.2 (11.4–13.0) 15.5 (13.5–17.6) (56) 2.8 (1.2) 0.6 (1.1) 2.2 (1.6)
6 m 67 27.0 (25.0–29.0) 12.1 (11.2–13.0) 14.9 (12.9–16.9) (55) 2.9 (1.1) 0.5 (1.0) 2.3 (1.4)
12 m 59 26.7 (24.9–28.5) 12.6 (11.6–13.7) 14.1 (12.3–15.8) (53) 2.9 (1.1) 0.6 (1.0) 2.3 (1.1)
18 m 29 24.6 (22.4–26.8) 12.5 (11.0–14.0) 12.1 (10.0–14.2) (49) 3.0 (0.8) 0.9 (1.2) 2.1 (1.6)
24 m 21 26.3 (22.8–29.9) 13.0 (11.5–14.4) 13.4 (10.4–16.4) (51) 2.7 (0.9) 0.9 (1.1) 1.8 (1.3)
GATT only
1 d 53 26.8 (24.7–29.0) 12.6 (11.1–14.0) 14.3 (11.7–16.9) (53) 3.0 (1.2) 0.3 (0.9) 2.8 (1.4)
1 w 50 27.0 (24.8–29.2) 14.2 (12.1–16.3) 12.8 (10.0–15.6) (47) 2.9 (1.2) 0.2 (0.7) 2.7 (1.4)
3 w 39 25.9 (23.4–28.5) 12.7 (11.3–14.2) 13.2 (10.1–16.3) (51) 2.9 (1.2) 0.5 (1.0) 2.5 (1.6)
6 w 31 27.5 (24.5–30.4) 13.2 (11.8–14.5) 14.3 (11.1–17.5) (52) 3.2 (1.2) 0.7 (1.3) 2.5 (1.8)
3 m 33 26.9 (24.3–29.5) 13.1 (11.8–14.3) 13.9 (11.6–16.2) (52) 3.0 (1.2) 0.9 (1.4) 2.1 (1.6)
6 m 33 26.8 (24.2–29.3) 12.3 (10.8–13.7) 14.5 (12.0–17.1) (54) 3.1 (1.1) 0.7 (1.1) 2.4 (1.4)
12 m 32 27.2 (24.6–29.7) 13.3 (11.7–15.0) 13.8 (11.3–16.3) (51) 2.9 (1.1) 0.9 (1.2) 2.0 (1.0)
18 m 15 25.0 (21.7–28.3) 11.8 (9.9–13.8) 13.2 (9.8–16.5) (53) 3.0 (0.8) 1.0 (1.3) 2.0 (1.6)
24 m 8 26.5 (19.9–33.1) 13.0 (10.7–15.3) 13.5 (7.6–19.4) (51) 3.0 (0.8) 0.9 (0.9) 2.1 (1.0)
Combined GATT and cataract surgery
1 d 49 27.4 (24.8–29.9) 13.6 (11.0–16.1) 13.8 (10.8–16.9) (50) 2.7 (1.1) 0.2 (0.7) 2.6 (1.3)
1 w 47 27.5 (24.9–30.1) 15.6 (13.5–17.8) 11.8 (8.7–15.0) (43) 2.7 (1.1) 0.5 (1.0) 2.2 (1.5)
3 w 42 28.0 (25.1–30.9) 11.8 (10.4–13.1) 16.2 (13.3–19.2) (58) 2.7 (1.1) 0.4 (0.9) 2.3 (1.5)
6 w 29 26.9 (24.2–29.7) 12.4 (11.2–13.7) 14.5 (11.8–17.2) (54) 2.6 (0.9) 0.2 (0.6) 2.4 (1.3)
3 m 35 28.5 (25.2–31.8) 11.4 (10.5–12.3) 17.1 (13.8–20.4) (60) 2.6 (1.2) 0.3 (0.7) 2.3 (1.5)
6 m 34 27.2 (23.9–30.5) 12.0 (10.9–13.1) 15.2 (12.0–18.4) (56) 2.6 (1.1) 0.3 (0.7) 2.3 (1.4)
12 m 27 26.2 (23.6–28.9) 11.8 (10.4–13.2) 14.4 (11.8–17.0) (55) 2.8 (1.0) 0.2 (0.6) 2.6 (1.2)
18 m 14 24.1 (20.9–27.4) 13.2 (10.6–15.8) 11.0 (8.2–13.8) (46) 3.0 (0.9) 0.8 (1.1) 2.2 (1.6)
24 m 13 26.2 (21.4–31.1) 12.9 (10.8–15.0) 13.3 (9.3–17.3) (51) 2.5 (1.0) 0.9 (1.2) 1.7 (1.4)
d, days; GATT, gonioscopy-assisted transluminal trabeculotomy; m, months, n, number of cases; w, weeks; #, number of medications.
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4 weeks, starting with every three hours during the first week
after surgery and then tapering to four times per day the second
week and two times per day the third week and one time per day
the fourth week. Pilocarpine 2% (Spersa-carpine, OmniVision
AG, Neuhausen am Rheinfall, Switzerland) three times per day
for 1 month and diclofenac 0.1% (Dicloabak, Théa Pharma,
Clermont-Ferrand, France) three time per day for 2 months. All
glaucoma medications were routinely stopped at day 1, unless
there was an IOP spike or steroid response during follow-up.
Postoperative examinations were performed at day 1, week 1,
week 3, week 6, month 3, month 6, month 12, month 18 and
month 24, or more frequently if clinically indicated by the phy-
sician. BCVA, IOP, number of glaucoma medications and all
complications were recorded.
Outcome measures
Primary outcomes were IOP and the number of glaucoma medica-
tions. Secondary outcomes were success rate, defined as IOP reduc-
tion ≥20% from baseline and IOP between 6 and 21 mm Hg
without further glaucoma surgery, and complication rate.
Hyphaema was defined as any blood seen in the anterior chamber
(AC) and was only considered a complication when it required
washout, either because it did not resolve in the first 2 weeks or if
therewas a complete hyphaema. IOP spikes (IOP≥26mmHg)were
only considered a complication when they were present on two
consecutive visits and lasted at least 2 weeks, defined as transient
hypertony. Transient hypotonywas defined as IOP lower than 6mm
Hg on two consecutive visits more than 2 weeks apart or when low
IOP was accompanied by maculopathy, a shallow or flat anterior
chamber, or choroidal effusions/haemorrhage.
Statistical analysis was performed with R version 3.6.1 (R
Core Team 2019. R: A language and environment for statistical
computing. Foundation for Statistical Computing, Vienna,
Austria). Normally distributed variables were reported as
means alongside SD and 95% CIs; non-normal variables were
reported as median and IQRs. Means of two continuous nor-
mally distributed variables were compared by independent sam-
ples Student’s t-test. Patients lost to follow-up were censored at
their last visit. Mean IOP and number of medication reductions
between preoperative value and postoperative value at a time
point were calculated only with the patients who had undergone
a visit at that time point.
RESULTS
Patient demographics are shown in table 1.
Combined cataract surgery with GATTwas performed in 50
eyes while the remaining 53 eyes were already pseudophakic.
Postoperative IOP was significantly lower than baseline at all
study time points for both groups, and there was no statistically
significant difference between both groups (p=0.652, Mann-
Whitney U test). There were no significant differences in glau-
coma medications between groups at any study time (p=0.179,
two-sample t-test). For all cases in this study, mean preoperative
IOP was 27.1 (95% CI 25.5 to 28.7) mm Hg using 2.9 (SD 1.1)
glaucoma medications. Postoperatively, IOP was 13.0 (95% CI
11.6 to 14.4) mm Hg at day 1, which corresponds to an IOP
reduction of 52% with a mean IOP of 14.1 (95% CI 12.1 to
16.0) mm Hg. Details of preoperative and postoperative IOP
and medication burden throughout follow-up are presented in
table 2 and figures 1 and 2.
Figure 1 Intraocular pressure (IOP) and number of medications at each time point over 24 months of follow-up. Each eye is represented with different
colours according to number of medications and with different symbols if continuing visit (dot) or if the time point represented the last visit (censoring).
The number of eyes and mean values are shown on the abscissa. The red circle represents the mean IOP value at each time point. d, days; m, months; w,
weeks.
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Complete GATT procedure (full 360º) was achieved in 97 of
103 eyes. In the six cases without 360º treatment, the mean IOP
difference between baseline and last postoperative time point was
12.07 (CI 95% 5.64–18.49, p=0.002) and mean medication
difference was −1.25 (CI 95% 0.16–2.35, p=0.029).
Mean BCVA (logMAR) was 0.3 (SD 0.3) before surgery, 0.2
(SD 0.4) at 12 months (p=0.155) and 0.4 (SD 0.8) at 24 months
(p=0.608). Overall success rate was 89.2% at 24 months.
Transient hyphaema was observed in all cases in the first post-
operative week and was usually suspended in viscoelastic in the
AC. By week 1, these had largely resolved. If hyphaema
persisted at week 1, eyes were reviewed at week 2. Micro-
hyphaema of <1 mm with IOP in the low teens rarely persisted
beyond 2 weeks and had no long-term consequences.
Conversely, if at week 1 there was a solid coagulated hyphaema
filling >50% of the AC (with or without elevated IOP), we
reviewed the patient at week 2 with a view to AC washout. In
table 3, we reported one case such a hyphaema which required
AC washout in the operating room.
There were 25 cases with isolated IOP spikes, but only 1 case
with transient hypertony as defined above. Overall complication
rate was 2.9% (table 3).
Figure 2 Scattergram of preoperative intraocular pressure (IOP) value (on the abscissa) and postoperative value (on the ordinate) at 6 months,
12 months, 18 months and 24 months of follow-up. The diagonal 45° line (solid black) indicates no change. Values between cut-off green lines at 6 and
21 mm Hg and under the diagonal that represents a 20% IOP decrease are classified as surgical success. Successful cases are spotted over a light green
background.
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The goal of glaucoma management is to preserve the patients’
quality of life by maintaining visual field and acuity with the least
possible adverse effects of therapy.10 It was not until the advent of
MIGS procedures,11 which aim to lower IOP with low complica-
tion rates and minimal tissue destruction that trabeculotomy
(originally described in 1960)12 experienced a renaissance.
MIGS aim at limiting conjunctival damage and the development
of bleb-less surgeries.13 Recent studies have underlined the
importance of the cost-effectiveness of MIGS and improving
patients’ quality of life.14
Grover et al reported their results for the GATT procedure in
POAG,15 16 in primary congenital glaucoma and juvenile open-
angle glaucoma17 and in patients with previous glaucoma
surgery,18 and other research groups reported similar results for
GATT in POAG19–21 and steroid-induced glaucoma.22 To the
best of our knowledge, there are no previous studies investigating
the outcomes of GATT in patients with PXG. Our results show
that GATT may be even more effective in PXG than in POAG, as
previously reported with limited ab interno trabeculectomy23 and
in some ab externo trabeculotomy studies.24 25
In our study, the marked reduction of IOP and number of
medications was statistically significant at all postoperative time
points. There were no major complications26 in any patient, and
the combination of cataract surgery and GATT maintained the
same effectiveness as GATTalone in pseudophakic patients. In 6
out of 103 eyes, a complete 360-degree trabeculotomy was not
achieved; however, all these partial cases were successful.
Hyphaema was observed in all cases at day 1, and if persistent,
this may lead to downstream complications27; however, it usually
resolved within the first 2 weeks. Conversely, hyphaema has also
been proposed as a positive prognostic factor following
canaloplasty.28
This study has some limitations: the non-comparative design, the
mid-term follow-up of up to 24 months and the thinning of our
data as some patients had their procedures performed less than 2
years before the end of this study. The procedure is cost-effective,
especially when using a polypropylene thread to circumnavigate
Schlemm’s canal, and the cost is considerably higher when the
microcatheter is used. We switched from catheter-GATT to suture-
GATT due to economic reasons, after 1 year into the study; there-
fore, a formal comparison between the two groups was not possible
due to limited follow-up. The procedure has a learning curve that
requires in-depth knowledge of angle anatomy. This technique also
requires an intact collector system, and currently, there is no reliable
preoperative method to assess the episcleral venous flow; however,
some intraoperative approaches have been suggested.29 30
In conclusion, our study demonstrates that GATT safely and
effectively lowers IOP in PXG, either when performed alone or
when performed in combination with cataract surgery. Given the
marked IOP lowering effect and low complication rates, and the
relatively aggressive nature of PXG, we consider GATT to be
a suitable first-line treatment for PXG patients. GATT, although
technically demanding, also provides a very cost-effective MIGS
procedure when a polypropylene suture is used.
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